Dulaglutide vs Liraglutide
A neutral, side-by-side comparison of two glp-1 & metabolic peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
Dulaglutide
Once-weekly GLP-1 receptor agonist (Trulicity) approved for type 2 diabetes and cardiovascular risk reduction. Engineered as a GLP-1 analogue fused to a modified IgG4-Fc domain, which provides a ~5-day half-life and enables once-weekly subcutaneous dosing via a simple auto-injector pen with no reconstitution required.
Full profileLiraglutide
Liraglutide is a once-daily GLP-1 receptor agonist — the first long-acting GLP-1 analog approved for both type 2 diabetes (Victoza, 1.8mg) and chronic weight management (Saxenda, 3mg). It was the foundational GLP-1 agonist that established the class's cardiovascular benefits and set the stage for semaglutide and tirzepatide.
Full profile| Dulaglutide | Liraglutide | |
|---|---|---|
| Category | GLP-1 & Metabolic | GLP-1 & Metabolic |
| Also known as | Trulicity, LY2189265 | NN2211, Victoza, Saxenda |
| Evidence | FDA-approved | FDA-approved |
| Dosing range | 0.75mg–4.5mg mg, once weekly subcutaneous | 0.6mg–3.0mg mg, Once daily subcutaneous injection |
| Administration | Subcutaneous injection (auto-injector pen) | Subcutaneous injection (abdomen, thigh, or upper arm) |
| Key side effects | Nausea (most common), Diarrhea, Vomiting, Abdominal pain | Nausea (most common, especially during initiation), Vomiting, Diarrhea, Decreased appetite |
| Cited sources | 2 references | 2 references |
Key differences
- Administration: Dulaglutide — Subcutaneous injection (auto-injector pen); Liraglutide — Subcutaneous injection (abdomen, thigh, or upper arm).
- Frequency: Dulaglutide is typically once weekly subcutaneous; Liraglutide is Once daily subcutaneous injection.
How each works
Dulaglutide
Dulaglutide's large molecular structure (fusion with IgG4-Fc) prevents renal filtration and extends half-life via FcRn recycling, enabling once-weekly dosing. The REWIND cardiovascular outcomes trial demonstrated significant reduction in major adverse cardiovascular events (MACE) in patients with or at risk for cardiovascular disease, establishing dulaglutide as a cardioprotective agent beyond glucose control.
Liraglutide
The LEADER trial (N=9340) demonstrated significant reduction in major adverse cardiovascular events (MACE) in high-risk T2D patients — the first cardiovascular outcomes trial for a GLP-1 agonist. The SCALE trials showed 5–8% mean weight loss at 3mg/day vs placebo. While superseded by semaglutide and tirzepatide in weight loss efficacy, liraglutide has the longest safety record in the class (approved 2010) and daily dosing allows finer tolerability titration.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.